Novartis India Limited operates as a healthcare company in India.
Novartis India Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹795.55|
|52 Week High||₹538.05|
|52 Week Low||₹1,099.00|
|1 Month Change||-6.52%|
|3 Month Change||-20.73%|
|1 Year Change||25.66%|
|3 Year Change||8.39%|
|5 Year Change||18.07%|
|Change since IPO||101.40%|
Recent News & Updates
|500672||IN Pharmaceuticals||IN Market|
Return vs Industry: 500672 exceeded the Indian Pharmaceuticals industry which returned 22.5% over the past year.
Return vs Market: 500672 underperformed the Indian Market which returned 64.8% over the past year.
Stable Share Price: 500672 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 500672's weekly volatility (5%) has been stable over the past year.
About the Company
Novartis India Limited operates as a healthcare company in India. It offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences, as well as generics products in the areas of gynecology, anti-TB, and anti-infectives. The company provides central nervous system products under the Tegrital and Exelon brands; pain and inflammation products under the Voveran brand; and transplantation/immunology products under the Simulect, Certican, Myfortic, and Sandimmun Neoral brands.
Novartis India Fundamentals Summary
|500672 fundamental statistics|
Is 500672 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|500672 income statement (TTM)|
|Cost of Revenue||₹1.51b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 11, 2021
|Earnings per share (EPS)||9.23|
|Net Profit Margin||5.89%|
How did 500672 perform over the long term?See historical performance and comparison
1.3%Current Dividend Yield
Is Novartis India undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500672 (₹795.55) is trading above our estimate of fair value (₹87.13)
Significantly Below Fair Value: 500672 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500672 is poor value based on its PE Ratio (86.2x) compared to the Indian Pharmaceuticals industry average (26.3x).
PE vs Market: 500672 is poor value based on its PE Ratio (86.2x) compared to the Indian market (21.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500672's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500672 is good value based on its PB Ratio (2.8x) compared to the IN Pharmaceuticals industry average (3.2x).
How is Novartis India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novartis India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Novartis India performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500672 has high quality earnings.
Growing Profit Margin: 500672's current net profit margins (5.9%) are higher than last year (3.2%).
Past Earnings Growth Analysis
Earnings Trend: 500672's earnings have declined by 40.5% per year over the past 5 years.
Accelerating Growth: 500672's earnings growth over the past year (66.6%) exceeds its 5-year average (-40.5% per year).
Earnings vs Industry: 500672 earnings growth over the past year (66.6%) exceeded the Pharmaceuticals industry 35.8%.
Return on Equity
High ROE: 500672's Return on Equity (3.2%) is considered low.
How is Novartis India's financial position?
Financial Position Analysis
Short Term Liabilities: 500672's short term assets (₹7.2B) exceed its short term liabilities (₹1.6B).
Long Term Liabilities: 500672's short term assets (₹7.2B) exceed its long term liabilities (₹1.3B).
Debt to Equity History and Analysis
Debt Level: 500672's debt to equity ratio (8.8%) is considered satisfactory.
Reducing Debt: 500672's debt to equity ratio has increased from 0.5% to 8.8% over the past 5 years.
Debt Coverage: 500672's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 500672 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Novartis India current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500672's dividend (1.26%) is higher than the bottom 25% of dividend payers in the Indian market (0.33%).
High Dividend: 500672's dividend (1.26%) is low compared to the top 25% of dividend payers in the Indian market (1.36%).
Stability and Growth of Payments
Stable Dividend: 500672's dividends per share have been stable in the past 10 years.
Growing Dividend: 500672's dividend payments have not increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (108.3%), 500672's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sanjay Murdeshwar (55 yo)
Mr. Sanjay Prabhakar Murdeshwar serves as Vice Chairman and Managing Director at Novartis India Limited since June 15, 2019. Mr. Murdeshwar served as Managing Director of AstraZeneca Pharma India Limited s...
CEO Compensation Analysis
Compensation vs Market: Sanjay's total compensation ($USD95.58K) is below average for companies of similar size in the Indian market ($USD191.33K).
Compensation vs Earnings: Sanjay's compensation has been consistent with company performance over the past year.
Experienced Management: 500672's management team is considered experienced (3 years average tenure).
Experienced Board: 500672's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Novartis India Limited's employee growth, exchange listings and data sources
- Name: Novartis India Limited
- Ticker: 500672
- Exchange: BSE
- Founded: 1947
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹19.643b
- Shares outstanding: 24.69m
- Website: https://www.novartis.in
Number of Employees
- Novartis India Limited
- Inspire BKC, G Block
- Part of 601 and 701
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/14 15:34|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.